Compare ARK Genomic Revolution ETF (ARKG) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs JPMorgan Chase & Co — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while JPMorgan Chase & Co trades at $338.44 (market cap $901.58B). The key difference: JPMorgan Chase & Co pays a 1.78% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | JPM | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $339.22 |
52-Week Low | $23.09 | $282.84 |
Market Cap | — | $901.58B |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
JPMorgan Chase (JPM) trades at $336.47, up 0.3% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $360.38. Recent earnings beat expectations in Q1 2026 with EPS of $5.94 versus $5.47 forecast, though Q4 2025 missed. Revenue grew to $181.85 billion in 2025, with a net income margin of 31.61% and ROE of 17.03%. The stock shows strong institutional interest amid positive media coverage on banking sector resilience.
Outlook remains positive given earnings momentum and high analyst buy ratings (51.67%), but risks include geopolitical tensions impacting oil markets and cybersecurity threats highlighted in recent news. Cash flow trends show significant financing activities offsetting negative operational flows, requiring monitoring of balance sheet leverage amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
